TITLE

The Effects of Minidose Heparin and Low Molecular Weight Heparin on Peritonitis in the Rat

AUTHOR(S)
Vela, A. Richard; Littleton, Jeffrey C.; O'Leary, J. Patrick
PUB. DATE
May 1999
SOURCE
American Surgeon;May1999, Vol. 65 Issue 5, p473
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents a study that evaluated the protective effect of regular heparin and of low molecular weight heparin (LMWH) Lovenox on peritonitis. Materials and methodology; Statistical difference on the survival rate between heparin and LMWH; Inflammatory process and therapeutic modalities of the disease.
ACCESSION #
1813010

 

Related Articles

  • Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia. Reilly, M.P.; Weiss, R.; Askenase, A.; Tuite, C.; Soulen, M.; Mohler III, E.R. // Vascular Medicine;2000, Vol. 5 Issue 4, p239 

    Heparin-induced thrombocytopenia (HIT) is the most common drug-related thrombocytopenia. Thromboembolic complications occur in approximately 50% of patients with HIT and result in limb amputation and death in up to 20% and 30% respectively. Because patients with a history of HIT may require...

  • A weight-based nomogram for heparin dosing.  // Patient Care;1/30/1994, Vol. 28 Issue 2, p100 

    Presents an overview of the scientific paper `The Weight-Based Heparin Dosing Nomogram Compared with a `Standard Care' Nomogram: A Randomized Control Trial,' by R.A. Rasschke, B.M. Reilly, J.R. Guidry and colleagues. Study of patients with venous or arterial thromboembolism or unstable angina;...

  • Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System.  // New England Journal of Medicine;3/18/2010, Vol. 362 Issue 11, p1056 

    A correction to the article "Contaminated Heparin Associated With Adverse Clinical Events and Activation of the Contact System" that was published in the June 5, 2008 issue is presented.

  • Effect of Heparin on the One--Stage Prothrombin Time. Moser, Kenneth M.; Hajjar, George C. // Annals of Internal Medicine;Jun67, Vol. 66 Issue 6, p1207 

    Presents a study that outlined the effects of various doses of intravenous and subcutaneous heparin on the one-stage prothrombin time. Effect of heparin on anticoagulant management of patients receiving heparin concomitantly with prothrombinopenic agents; Description of a patient with...

  • Heparin prophylaxis for medical patients? Lederle, Frank A.; Lederle, F A // Annals of Internal Medicine;05/01/98, Vol. 128 Issue 9, p768 

    Editorial. Provides information on the establishment of heparin prophylaxis for surgical patients. Effectiveness of prophylaxis in hospitalized medical patients; Reference to study conducted; Average cost of prophylaxis per patient.

  • Heparin-associated Thrombocytopenia. King, Derek J.; Kelton, John G. // Annals of Internal Medicine;Apr84, Vol. 100 Issue 4, p535 

    Presents a study which examined the occurrence of thrombocytopenia in patients receiving heparin therapy. Complications of heparin therapy; Details of the clinical characteristics of patients involved in the study; Discussion on the management of patients who receive heparin therapy.

  • Randomised Long-Term Comparison of Tinzaparin and Dalteparin in Haemodialysis. Beijering, R.J.R.; ten Cate, H.; Stevens, P.; Vanholder, R.; van Dorp, W.T.; van Olden, R.W.; Wickström, B.; Sprøgel, P.; ten Cate, J.W. // Clinical Drug Investigation;2003, Vol. 23 Issue 2, p85 

    Objective and design: Tinzaparin and dalteparin are low molecular weight heparins (LMWHs) with different pharmacokinetic and pharmacodynamic profiles that may lead to differences in efficacy and safety. In a long-term, multicentre, prospective, randomised trial we compared the efficacy and...

  • Anticoagulation in heart disease. Hardman, Suzanna M C; Cowie, Martin R; Bettelheim, Eric // BMJ: British Medical Journal (International Edition);01/23/99, Vol. 318 Issue 7178, p238 

    Presents information on a study which discusses the use of warfarin and heparin in patients with heart disease. Methodology; Information on non-rheumatic atrial fibrillation; Factors which increase the risk of thromboembolism; Details on paroxysmal atrial fibrillation.

  • Dalteparin sodium/heparin.  // Reactions Weekly;6/5/2010, Issue 1304, p14 

    The article describes the case of a 70-year-old man who acquired thrombocytopenia and fatal venous thromboses following treatment with heparin and dalteparin sodium.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics